William F Anderson1, Kenneth C Chu, Shine Chang. 1. National Cancer Institute, Division of Cancer Prevention, EPN, Room 2144, 6130 Executive Blvd, Bethesda, MD 20892-7317, USA. wanderso@mail.nih.gov
Abstract
PURPOSE: Inflammatory breast carcinoma (IBC) and noninflammatory locally advanced breast carcinoma (LABC) are both associated with poor prognosis; however, whether they are distinct clinicopathologic entities remains controversial. MATERIALS AND METHODS: To determine whether IBC and LABC were different, we compared tumor characteristics, prognosis, and age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program. An age of 50 years served as a surrogate marker for menopause. RESULTS: Younger age at diagnosis, poorer tumor grade, and negative estrogen receptors (ERs) were more predictive of IBC (n = 2,237) than of LABC (n = 7,985). Breast carcinoma survival was worse for patients with IBC than for those with LABC (log-rank test, P <.0001). Age-specific incidence rates for IBC increased until 50 years and then flattened, whereas rates for LABC increased for all ages. When rates for LABC were stratified by estrogen receptor-positive (ERP) and -negative (ERN) expression, rates for ERP and ERN diverged; that is, rates for ERP increased with advancing age, whereas rates for ERN flattened after 50 years. When rates for IBC were stratified by ER expression, rates for both ERP and ERN flattened after 50 years of age. CONCLUSION: IBC and LABC seemed to be distinct biologic entities, as indicated by different prognostic factor profiles and age-specific incidence rate patterns. Rates that increased before 50 years and then stabilized, possibly indicated that premenopausal exposures had a greater effect on maintaining rates for IBC than for LABC.
PURPOSE: Inflammatory breast carcinoma (IBC) and noninflammatory locally advanced breast carcinoma (LABC) are both associated with poor prognosis; however, whether they are distinct clinicopathologic entities remains controversial. MATERIALS AND METHODS: To determine whether IBC and LABC were different, we compared tumor characteristics, prognosis, and age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program. An age of 50 years served as a surrogate marker for menopause. RESULTS: Younger age at diagnosis, poorer tumor grade, and negative estrogen receptors (ERs) were more predictive of IBC (n = 2,237) than of LABC (n = 7,985). Breast carcinoma survival was worse for patients with IBC than for those with LABC (log-rank test, P <.0001). Age-specific incidence rates for IBC increased until 50 years and then flattened, whereas rates for LABC increased for all ages. When rates for LABC were stratified by estrogen receptor-positive (ERP) and -negative (ERN) expression, rates for ERP and ERN diverged; that is, rates for ERP increased with advancing age, whereas rates for ERN flattened after 50 years. When rates for IBC were stratified by ER expression, rates for both ERP and ERN flattened after 50 years of age. CONCLUSION: IBC and LABC seemed to be distinct biologic entities, as indicated by different prognostic factor profiles and age-specific incidence rate patterns. Rates that increased before 50 years and then stabilized, possibly indicated that premenopausal exposures had a greater effect on maintaining rates for IBC than for LABC.
Authors: Catherine Schairer; Shahinaz M Gadalla; Ruth M Pfeiffer; Steven C Moore; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-13 Impact factor: 4.254
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2012-06-26 Impact factor: 4.872
Authors: Carolyn S Hall; Mandar Karhade; Barbara A Laubacher; Henry M Kuerer; Savitri Krishnamurthy; Sarah DeSnyder; Amber E Anderson; Vicente Valero; Naoto T Ueno; Yisheng Li; Xiao Su; Anthony Lucci Journal: J Natl Cancer Inst Date: 2015-09-14 Impact factor: 13.506
Authors: Dora Il'yasova; Sharareh Siamakpour-Reihani; Igor Akushevich; Lucy Akushevich; Neil Spector; Joellen Schildkraut Journal: Breast Cancer Res Treat Date: 2011-08-18 Impact factor: 4.872
Authors: Katherine M Aird; Rami B Ghanayem; Sharon Peplinski; Herbert K Lyerly; Gayathri R Devi Journal: Mol Cancer Ther Date: 2010-04-20 Impact factor: 6.261
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; Mousumi Banerjee; Laura S Rozek; David Schottenfeld; Joe B Harford; Sofia D Merajver Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10-25 Impact factor: 4.254
Authors: Catherine Schairer; Yan Li; Peter Frawley; Barry I Graubard; Robert D Wellman; Diana S M Buist; Karla Kerlikowske; Tracy L Onega; William F Anderson; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: J Lemieux; M Clemons; L Provencher; S Dent; J Latreille; J Mackey; K I Pritchard; D Rayson; Sh Verma; Su Verma; B Wang; S Chia Journal: Curr Oncol Date: 2009-09 Impact factor: 3.677